KeriMedical is now a strong partner of Medovent GmbH and has exclusively acquired the license rights for the product line Reaxon® for orthopedic care.
We are looking forward to join the 38. Symposium of the BG Klinik Ludwigshafen (Germany) at May the 13th 2017. Please find further information: Symposium BG Ludwigshafen
The Medovent team will be pleased to meet you during the 58. DAH Symposium in Münster (Germany) from May the 4th–6th 2017. Visit us at the booth. Please find further information: DAH 2017
Reaxon® Nerve Guide and Reaxon® Direct are now available in France.
With the CE-certification of Reaxon® Direct, the Reaxon® product family is expanding. Reaxon® Direct allows the tension-free supply of short nerve defects and offers an optimal protection against scar tissue and painful neuroma formation.
Reaxon® Nerve Guide is also available for surgeons in Austria, Italy, and Switzerland.
Medovent has started a project on new designs for the treatment of digital nerve defects in collaboration with the Institute of Neuroanatomy at the Hannover Medical School.
The chitosan nerve conduit Reaxon® Nerve Guide for the treatment of peripheral nerve injuries receives the CE certificate.
Medoderm receives the CE certificate for Quractiv® Derm – the wound dressing made of Chitosan-FH02 developed in collaboration with Medovent.
Medovent starts the commercialization of chitosan microfibers for biomedical research.
As a partners of the European project BIOHYBRID, Medovent along with nine other institutions, hospitals and companies from Germany, Israel, Italy, Portugal, Spain, and Sweden, start the development of innovative conduits for the repair of peripheral nerves. Further information: BIOHYBRID
Medovent successfully finishes the testing of a new coating process. Medical devices can be provided with a thin chitosan surface without altering the natural properties of the biomaterial.
Medovent receives the EN ISO 13485 certificate for the production and development of chitosan-based medical devices.